Press Release

First results of MA.32 trial: Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals

World Cancer Day 2022: the DECRESCENDO study

OlympiA trial – olaparib reduces risk of death by 32% in patients with a specific breast cancer profile

Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer

Pink October 2022 – BIG Missing Campaign

Breast International Group (BIG) – aisbl

Head Office

Tax Deduction

Donations greater than or equal to € 40 / year receive a 45% tax reduction. This means your donation of €40 only costs you € 22.

Site Links

The Breast International Group is proud to adhere to the Code of Ethics of the RE-EF.

Co-funded by the European Union under an operating grant from the European Union’s EU4Health programme under grant agreement No 101124555. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

EN FR NL